glp-1 review article receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1-based therapies for diabetes, obesity

18.Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study

When transitioning from semaglutide to another diabetes medication, clinicians should anticipate overlapping drug effects for several weeks

[34].Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjornsdottir I, Pedersen PJ, Rowe E, Derving Karsbol J, Pedersen ML, Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 104 (2017) 3141

Next Steps: Taking Action with GLP-1 Therapies Consult a Healthcare Professional: Discuss your eligibility for GLP-1 agonists with a doctor or endocrinologist

Recent clinical trials have shown impressive results, with many individuals, both diabetic and non-diabetic, achieving significant weight reduction

Gabery, S